"I don't suggest anybody read about their cancer and life expectancy on Google because number 1, don't believe it. Number 2, fight." Hear from Fred Neubauer, Cholangiocarcinoma Survivor and Patient Advocate about his Cholangiocarcinoma story and how biomarker targeted therapies influenced his Cholangiocarcinoma care journey during this video recorded during the Lunch, Learn & Live event held on May 21, 2024 at the Graylyn Estates in Winston-Salem, NC, co-hosted with Cancer Services.
About the Speaker
Fred Neubauer
Cholangiocarcinoma Survivor & Patient Advocate Cholangiocarcinoma Patient Story- he Benefits of Mutation Burden Testing
Fred Neubauer is a recently retired sales manager with Specialty Chemical Corporation. He was diagnosed with stage 4 Intrahepatic Cholangiocarcinoma which had metastasized to his bones and lung in October 2019. His initial treatment plan included a year of chemotherapy, along with 3 weeks of external beam precision radiation. Fred has now been on targeted gene therapy for over three years. He is a volunteer patient mentor and research advocate with the Cholangiocarcinoma Foundation.
The Lunch, Learn & Live event was made possible in-part by grants from Lilly and Foundation Medicine.
This Video Content has been made available for informational and educational purposes only. The Video Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or seen on the Site.
LiveLung and speakers hereby disclaim any and all liability to any party for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising directly or indirectly from any use of the Video Content, which is provided as is, and without warranties.